STOCKHOLM, SWEDEN--(Marketwire - March 26, 2010) - Biovitrum AB (publ) announces by issuing of a press release the content of the notice to the Annual General Meeting 2010.
Attachment: - Notice to the Annual General Meeting 2010 of Biovitrum AB (publ) For further information please contact: Martin Nicklasson, CEO Phone: +46 8 697 20 00 Göran Arvidson, CFO Cell phone: +46 70 633 30 42 Erik Kinnman, VP Investor Relations Cell phone: +46 73 422 15 40 erik.kinnman@biovitrum.com About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading company focused on treatment of rare diseases.
Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company with an international market presence. The company is focused on providing and developing orphan and niche specialist pharmaceuticals to patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipeline within rare diseases. Swedish Orphan Biovitrum has pro-forma revenues 2009 of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: BVT) is listed on NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com.
The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 8.30 a.m. CET on March 26, 2010.
[HUG#1397952]
Notice AGM 2010: http://hugin.info/134557/R/1397952/353729.pdf
Press release PDF: http://hugin.info/134557/R/1397952/353721.pdf
